ATE524450T1 - 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren - Google Patents

5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren

Info

Publication number
ATE524450T1
ATE524450T1 AT08786712T AT08786712T ATE524450T1 AT E524450 T1 ATE524450 T1 AT E524450T1 AT 08786712 T AT08786712 T AT 08786712T AT 08786712 T AT08786712 T AT 08786712T AT E524450 T1 ATE524450 T1 AT E524450T1
Authority
AT
Austria
Prior art keywords
isoxazole
acute
carboxamide derivatives
phenyl
disorders
Prior art date
Application number
AT08786712T
Other languages
English (en)
Inventor
Andrew Roughton
Koc-Kan Ho
Michael Ohlmeyer
Irina Neagu
Steven Kultgen
Nasrin Ansari
Yajing Rong
Paul Ratcliffe
Ronald Palin
Original Assignee
Organon Nv
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv, Pharmacopeia Llc filed Critical Organon Nv
Application granted granted Critical
Publication of ATE524450T1 publication Critical patent/ATE524450T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08786712T 2007-08-02 2008-07-31 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren ATE524450T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95349307P 2007-08-02 2007-08-02
US1370007P 2007-12-14 2007-12-14
PCT/EP2008/060090 WO2009016241A1 (en) 2007-08-02 2008-07-31 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators

Publications (1)

Publication Number Publication Date
ATE524450T1 true ATE524450T1 (de) 2011-09-15

Family

ID=39925074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08786712T ATE524450T1 (de) 2007-08-02 2008-07-31 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren

Country Status (8)

Country Link
US (1) US8211927B2 (de)
EP (1) EP2185530B1 (de)
JP (1) JP2011511756A (de)
CN (1) CN101796036A (de)
AT (1) ATE524450T1 (de)
CA (1) CA2694663A1 (de)
MX (1) MX2010001236A (de)
WO (1) WO2009016241A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151947A1 (en) 2008-05-27 2009-12-17 Qualcomm Incorporated Setting up a communication session within a wireless communications system
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
TW201623288A (zh) 2014-05-14 2016-07-01 諾華公司 甲醯胺衍生物
TW201946921A (zh) 2014-05-14 2019-12-16 瑞士商諾華公司 甲醯胺衍生物
US10174014B2 (en) * 2014-06-19 2019-01-08 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US10865181B2 (en) 2014-11-05 2020-12-15 University Of Kansas Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105484A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US20180147187A1 (en) * 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3325474A1 (de) 2015-07-24 2018-05-30 Proteostasis Therapeutics, Inc. Verbindungen, zusammensetzungen und verfahren zur steigerung der cftr-aktivität
NZ741093A (en) 2015-10-06 2022-12-23 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
NZ746793A (en) 2016-04-07 2022-10-28 Proteostasis Therapeutics Inc Silicone atoms containing ivacaftor analogues
EP3472156B1 (de) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Verbindungen, zusammensetzungen und verfahren zur steigerung der cftr-aktivität
KR20210018915A (ko) * 2018-06-08 2021-02-18 베타 파머수티컬 컴퍼니 리미티드 Erk 억제제 및 이의 용도
CN111518044A (zh) * 2019-02-01 2020-08-11 华东师范大学 烷氧基异噁唑类衍生物及其制备方法与应用
CA3152534A1 (en) * 2019-09-27 2021-04-01 Collaborations Pharmaceuticals, Inc. Isoxazole-3-carboxamide derivatives and their use for treatment of diseases caused by virus infection
CN115105503B (zh) * 2022-07-20 2023-05-23 河南大学 一种trpv1拮抗/cox抑制双靶点药物或其药学上可接受的盐、药物制剂和应用
CN118955415A (zh) * 2024-07-30 2024-11-15 深圳智微通科技有限公司 一种5-(2,4-二氟苯基)异噁唑-3-甲酸乙酯的连续合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1

Also Published As

Publication number Publication date
CN101796036A (zh) 2010-08-04
WO2009016241A1 (en) 2009-02-05
JP2011511756A (ja) 2011-04-14
MX2010001236A (es) 2010-03-04
EP2185530B1 (de) 2011-09-14
EP2185530A1 (de) 2010-05-19
US8211927B2 (en) 2012-07-03
CA2694663A1 (en) 2009-02-05
US20110065764A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
NO20084328L (no) Nye forbindelser
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EP2051760A4 (de) Verabreichung einer atemtherapie
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EP2282795A4 (de) Behandlung von atemwegserkrankungen
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
DK2150530T3 (da) Substituerede sulfonamid-derivater
EA201100503A1 (ru) Глюкозидные производные и их применения
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
ATE517882T1 (de) Chinolinderivate
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EP2211956A4 (de) Abgabe von osmolyten mit einer nasenkanüle
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
ATE543804T1 (de) Neue verbindungen
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties